Design Synthesis And Evaluation Of Multitarget Directed Ligands In Alzheimer s Disease Treatment

Abstract

Alzheimer s disease (AD) is a multifaceted neurodegenerative disease, which majorly targets newlinethe senior population. It is the most common form of dementia, which worsens the cognitive newlinefunctions and memory of the human brain. The continuous failure of FDA approved drugs in newlineclinical trials and an increase in the number of affected population demands an urgent need newlinefor effective therapeutic strategies. The main reason for the failure of AD drugs is mainly due newlineto the complex nature of AD and the root cause of this disease is still undefined. newlineHistologically, the major causes of AD are the decrease in acetylcholine level, the formation newlineof amyloidand#8722;beta (Aand#946;) deposits, oxidative stress, neurofibrillary tangles (NFTs) of tau protein newlineand dyshomeostasis of biometals. These factors were seen to be interconnected during the newlineprogression of AD. Therefore, the design of multifunctional compounds that can target newlineseveral pathologies of disease at the same time could be an effective approach to halt the newlineprogression of AD. Here, the various reports related to multifunctional ligands as inhibitors newlineof butyrylcholinesterase (BuChE), acetylcholinesterase (AChE), and#947;and#8722;secretase, and#946;and#8722;secretase, tau newlinemisfolding, (Aand#946;) aggregation and oxidative stress etc. have been outlined and discussed their newlinepotential therapeutic role in AD s treatment. newline